Comparison results for median (25th percentile-75th percentile) damage degree scores for liver and heart tissues. by Ayça Toprak-Semiz (22582110)

Subjects:

Comparison results for n (%) of damage degree scores for liver and heart tissues. by Ayça Toprak-Semiz (22582110)

Subjects:

Histopathological appearance of the liver. by Ayça Toprak-Semiz (22582110)

Subjects:

Histopathological appearance of the heart. by Ayça Toprak-Semiz (22582110)

Subjects:

Effects of HFCS and hazelnut on food intake, liquid intake and body weights in groups of rats. by Ayça Toprak-Semiz (22582110)

Subjects:

Effects of HFCS and hazelnut on biochemical parameters in groups of rats. by Ayça Toprak-Semiz (22582110)

Subjects:

This is the raw data used for this study. by James M. Friedman (22522150)

Subjects:

Pre-operative versus post-operative symptoms. by James M. Friedman (22522150)

Subjects:

The Human Disharmony Loop (full) Including Inciting Factors. by James M. Friedman (22522150)

Subjects:

Baseline Severity of Disease by Scapular Dyskinesia Stage^1. by James M. Friedman (22522150)

Subjects:

The Human Disharmony Loop Clinical Presentation. by James M. Friedman (22522150)

Subjects:

Patient Demographics. by James M. Friedman (22522150)

Subjects:

Pain and Function Outcomes Following PM Tenotomy. by James M. Friedman (22522150)

Subjects:

Diagnostic Criteria for Human Disharmony Loop. by James M. Friedman (22522150)

Subjects:

Normal Anatomy vs. Disharmonic Pathoanatomy. by James M. Friedman (22522150)

Subjects:

The Human Disharmony Loop (central). by James M. Friedman (22522150)

Subjects:

Sample Pain Diagrams. by James M. Friedman (22522150)

Subjects:

Patient Example. by James M. Friedman (22522150)

Subjects:

Summary of study eligibility criteria. by Biban Gill (1473337)

“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”

Summary of study participation and feasibility. by Biban Gill (1473337)

“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”